APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilars of Rituximab

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Biosimilars of Rituximab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026197 pages

Choose your research edition.

Industry ResearchBiosimilars of Rituximab Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilars of Rituximab Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Biosimilars of Rituximab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilars of Rituximab Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilars of Rituximab Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Biosimilars of Rituximab market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Biosimilars of Rituximab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biosimilars of Rituximab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biosimilars of Rituximab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Biosimilars of Rituximab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biosimilars of Rituximab include AryoGen Pharmed, Biocad, Cadila Pharmaceuticals, Celltrion, Dr Reddy’s Laboratories, Hetero Group, Innovent Biologics, Intas Biopharmaceuticals and Probiomed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biosimilars of Rituximab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biosimilars of Rituximab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilars of Rituximab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biosimilars of Rituximab market size, projected growth trends, production technologies, key applications, and end-use industries.

Biosimilars of Rituximab Segment by Company

AryoGen Pharmed

Biocad

Cadila Pharmaceuticals

Celltrion

Dr Reddy’s Laboratories

Hetero Group

Innovent Biologics

Intas Biopharmaceuticals

Probiomed

TRPharma

Viatris

Zenotech Laboratories

Amgen

Teva

Biosimilars of Rituximab Segment by Type

500mg

100mg

Other

Biosimilars of Rituximab Segment by Application

Hospital Pharmacy

Retail Pharmacy

Biosimilars of Rituximab Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars of Rituximab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilars of Rituximab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars of Rituximab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilars of Rituximab market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biosimilars of Rituximab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biosimilars of Rituximab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biosimilars of Rituximab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Biosimilars of Rituximab Industry Trends Table 2. Biosimilars of Rituximab Industry Drivers Table 3. Biosimilars of Rituximab Industry Opportunities and Challenges Table 4. Biosimilars of Rituximab Industry Restraints Table 5. Global Biosimilars of Rituximab Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Biosimilars of Rituximab Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Biosimilars of Rituximab Sales by Manufacturers (K Pcs) & (2021-2026) Table 8. Global Biosimilars of Rituximab Sales Market Share by Manufacturers Table 9. Global Biosimilars of Rituximab Average Sales Price (US$/Pcs) of Manufacturers (2021-2026) Table 10. Global Biosimilars of Rituximab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Biosimilars of Rituximab Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Biosimilars of Rituximab Manufacturers, Product Type & Application Table 13. Global Biosimilars of Rituximab Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Biosimilars of Rituximab by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 500mg Table 17. Major Manufacturers of 100mg Table 18. Major Manufacturers of Other Table 19. Global Biosimilars of Rituximab Sales by Type 2021 VS 2025 VS 2032 (K Pcs) Table 20. Global Biosimilars of Rituximab Sales by Type (2021-2026) & (K Pcs) Table 21. Global Biosimilars of Rituximab Sales by Type (2027-2032) & (K Pcs) Table 22. Global Biosimilars of Rituximab Sales Market Share by Type (2021-2026) Table 23. Global Biosimilars of Rituximab Sales Market Share by Type (2027-2032) Table 24. Global Biosimilars of Rituximab Revenue by Type 2021 VS 2025 VS 2032 (K Pcs) Table 25. Global Biosimilars of Rituximab Revenue by Type (2021-2026) & (K Pcs) Table 26. Global Biosimilars of Rituximab Revenue by Type (2027-2032) & (K Pcs) Table 27. Global Biosimilars of Rituximab Revenue Market Share by Type (2021-2026) Table 28. Global Biosimilars of Rituximab Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Pharmacy Table 30. Major Manufacturers of Retail Pharmacy Table 31. Global Biosimilars of Rituximab Sales by Application 2021 VS 2025 VS 2032 (K Pcs) Table 32. Global Biosimilars of Rituximab Sales by Application (2021-2026) & (K Pcs) Table 33. Global Biosimilars of Rituximab Sales by Application (2027-2032) & (K Pcs) Table 34. Global Biosimilars of Rituximab Sales Market Share by Application (2021-2026) Table 35. Global Biosimilars of Rituximab Sales Market Share by Application (2027-2032) Table 36. Global Biosimilars of Rituximab Revenue by Application 2021 VS 2025 VS 2032 (K Pcs) Table 37. Global Biosimilars of Rituximab Revenue by Application (2021-2026) & (K Pcs) Table 38. Global Biosimilars of Rituximab Revenue by Application (2027-2032) & (K Pcs) Table 39. Global Biosimilars of Rituximab Revenue Market Share by Application (2021-2026) Table 40. Global Biosimilars of Rituximab Revenue Market Share by Application (2027-2032) Table 41. Global Biosimilars of Rituximab Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Table 42. Global Biosimilars of Rituximab Sales by Region (2021-2026) & (K Pcs) Table 43. Global Biosimilars of Rituximab Sales Market Share by Region (2021-2026) Table 44. Global Biosimilars of Rituximab Sales Forecasted by Region (2027-2032) & (K Pcs) Table 45. Global Biosimilars of Rituximab Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Biosimilars of Rituximab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 47. North America Biosimilars of Rituximab Sales by Country (2021-2026) & (K Pcs) Table 48. North America Biosimilars of Rituximab Sales by Country (2027-2032) & (K Pcs) Table 49. Europe Biosimilars of Rituximab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 50. Europe Biosimilars of Rituximab Sales by Country (2021-2026) & (K Pcs) Table 51. Europe Biosimilars of Rituximab Sales by Country (2027-2032) & (K Pcs) Table 52. Asia Pacific Biosimilars of Rituximab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 53. Asia Pacific Biosimilars of Rituximab Sales by Country (2021-2026) & (K Pcs) Table 54. Asia Pacific Biosimilars of Rituximab Sales by Country (2027-2032) & (K Pcs) Table 55. South America, Middle East and Africa Biosimilars of Rituximab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 56. South America, Middle East and Africa Biosimilars of Rituximab Sales by Country (2021-2026) & (K Pcs) Table 57. South America, Middle East and Africa Biosimilars of Rituximab Sales by Country (2027-2032) & (K Pcs) Table 58. Global Biosimilars of Rituximab Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Biosimilars of Rituximab Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Biosimilars of Rituximab Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Biosimilars of Rituximab Revenue Market Share by Region (2021-2026) Table 62. Global Biosimilars of Rituximab Revenue Market Share by Region (2027-2032) Table 63. AryoGen Pharmed Company Information Table 64. AryoGen Pharmed Business Overview Table 65. AryoGen Pharmed Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AryoGen Pharmed Biosimilars of Rituximab Product Portfolio Table 67. AryoGen Pharmed Recent Development Table 68. Biocad Company Information Table 69. Biocad Business Overview Table 70. Biocad Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Biocad Biosimilars of Rituximab Product Portfolio Table 72. Biocad Recent Development Table 73. Cadila Pharmaceuticals Company Information Table 74. Cadila Pharmaceuticals Business Overview Table 75. Cadila Pharmaceuticals Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Cadila Pharmaceuticals Biosimilars of Rituximab Product Portfolio Table 77. Cadila Pharmaceuticals Recent Development Table 78. Celltrion Company Information Table 79. Celltrion Business Overview Table 80. Celltrion Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Celltrion Biosimilars of Rituximab Product Portfolio Table 82. Celltrion Recent Development Table 83. Dr Reddy’s Laboratories Company Information Table 84. Dr Reddy’s Laboratories Business Overview Table 85. Dr Reddy’s Laboratories Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Dr Reddy’s Laboratories Biosimilars of Rituximab Product Portfolio Table 87. Dr Reddy’s Laboratories Recent Development Table 88. Hetero Group Company Information Table 89. Hetero Group Business Overview Table 90. Hetero Group Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Hetero Group Biosimilars of Rituximab Product Portfolio Table 92. Hetero Group Recent Development Table 93. Innovent Biologics Company Information Table 94. Innovent Biologics Business Overview Table 95. Innovent Biologics Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Innovent Biologics Biosimilars of Rituximab Product Portfolio Table 97. Innovent Biologics Recent Development Table 98. Intas Biopharmaceuticals Company Information Table 99. Intas Biopharmaceuticals Business Overview Table 100. Intas Biopharmaceuticals Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Intas Biopharmaceuticals Biosimilars of Rituximab Product Portfolio Table 102. Intas Biopharmaceuticals Recent Development Table 103. Probiomed Company Information Table 104. Probiomed Business Overview Table 105. Probiomed Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Probiomed Biosimilars of Rituximab Product Portfolio Table 107. Probiomed Recent Development Table 108. TRPharma Company Information Table 109. TRPharma Business Overview Table 110. TRPharma Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. TRPharma Biosimilars of Rituximab Product Portfolio Table 112. TRPharma Recent Development Table 113. Viatris Company Information Table 114. Viatris Business Overview Table 115. Viatris Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Viatris Biosimilars of Rituximab Product Portfolio Table 117. Viatris Recent Development Table 118. Zenotech Laboratories Company Information Table 119. Zenotech Laboratories Business Overview Table 120. Zenotech Laboratories Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Zenotech Laboratories Biosimilars of Rituximab Product Portfolio Table 122. Zenotech Laboratories Recent Development Table 123. Amgen Company Information Table 124. Amgen Business Overview Table 125. Amgen Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Amgen Biosimilars of Rituximab Product Portfolio Table 127. Amgen Recent Development Table 128. Teva Company Information Table 129. Teva Business Overview Table 130. Teva Biosimilars of Rituximab Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Teva Biosimilars of Rituximab Product Portfolio Table 132. Teva Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Biosimilars of Rituximab Distributors List Table 136. Biosimilars of Rituximab Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Biosimilars of Rituximab Product Image Figure 2. Global Biosimilars of Rituximab Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilars of Rituximab Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilars of Rituximab Sales (2021-2032) & (K Pcs) Figure 5. Global Biosimilars of Rituximab Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Top 5 and 10 Biosimilars of Rituximab Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 500mg Image Figure 9. 100mg Image Figure 10. Other Image Figure 11. Global Biosimilars of Rituximab Sales by Type (2021 VS 2025 VS 2032) & (K Pcs) Figure 12. Global Biosimilars of Rituximab Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Biosimilars of Rituximab Sales Market Share by Type (2021-2032) Figure 14. Global Biosimilars of Rituximab Revenue by Type (2021 VS 2025 VS 2032) & (K Pcs) Figure 15. Global Biosimilars of Rituximab Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Biosimilars of Rituximab Revenue Market Share by Type (2021-2032) Figure 17. Hospital Pharmacy Image Figure 18. Retail Pharmacy Image Figure 19. Global Biosimilars of Rituximab Sales by Application (2021 VS 2025 VS 2032) & (K Pcs) Figure 20. Global Biosimilars of Rituximab Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Biosimilars of Rituximab Sales Market Share by Application (2021-2032) Figure 22. Global Biosimilars of Rituximab Revenue by Application (2021 VS 2025 VS 2032) & (K Pcs) Figure 23. Global Biosimilars of Rituximab Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Biosimilars of Rituximab Revenue Market Share by Application (2021-2032) Figure 25. North America Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 26. North America Biosimilars of Rituximab Sales Market Share by Country (2021-2032) Figure 27. U.S. Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 28. Canada Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 29. Mexico Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 30. Europe Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 31. Europe Biosimilars of Rituximab Sales Market Share by Country (2021-2032) Figure 32. Germany Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 33. France Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 34. U.K. Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 35. Italy Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 36. Netherlands Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 37. Asia Pacific Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 38. Asia Pacific Biosimilars of Rituximab Sales Market Share by Country (2021-2032) Figure 39. China Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 40. Japan Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 41. South Korea Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 42. Southeast Asia Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 43. India Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 44. Australia Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 45. South America, Middle East and Africa Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 46. South America, Middle East and Africa Biosimilars of Rituximab Sales Market Share by Country (2021-2032) Figure 47. Brazil Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 48. South Africa Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 49. Saudi Arabia Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 50. Turkey Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 51. Argentina Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 52. UAE Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 53. Egypt Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 54. Chile Biosimilars of Rituximab Sales and Growth Rate (2021-2032) & (K Pcs) Figure 55. Global Biosimilars of Rituximab Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Biosimilars of Rituximab Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Biosimilars of Rituximab Revenue (2021-2032) & (US$ Million) Figure 58. North America Biosimilars of Rituximab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Biosimilars of Rituximab Revenue (2021-2032) & (US$ Million) Figure 60. Europe Biosimilars of Rituximab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Biosimilars of Rituximab Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Biosimilars of Rituximab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Biosimilars of Rituximab Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Biosimilars of Rituximab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Biosimilars of Rituximab Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Biosimilars of Rituximab Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 500mg
  • 100mg
  • Other
Applications
  • Hospital Pharmacy
  • Retail Pharmacy
Companies covered
  • AryoGen Pharmed
  • Biocad
  • Cadila Pharmaceuticals
  • Celltrion
  • Dr Reddy’s Laboratories
  • Hetero Group
  • Innovent Biologics
  • Intas Biopharmaceuticals
  • Probiomed
  • TRPharma
  • Viatris
  • Zenotech Laboratories
  • Amgen
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biosimilars of Rituximab Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biosimilars of Rituximab Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Biosimilars of Rituximab Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Biosimilars of Rituximab Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Biosimilars of Rituximab Market Dynamics
  1. 2.1 Biosimilars of Rituximab Industry Trends
  2. 2.2 Biosimilars of Rituximab Industry Drivers
  3. 2.3 Biosimilars of Rituximab Industry Opportunities and Challenges
  4. 2.4 Biosimilars of Rituximab Industry Restraints
3 Biosimilars of Rituximab Market by Manufacturers
  1. 3.1 Global Biosimilars of Rituximab Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Biosimilars of Rituximab Sales by Manufacturers (2021-2026)
  3. 3.3 Global Biosimilars of Rituximab Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Biosimilars of Rituximab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biosimilars of Rituximab Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Biosimilars of Rituximab Manufacturers, Product Type & Application
  7. 3.7 Global Biosimilars of Rituximab Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biosimilars of Rituximab Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biosimilars of Rituximab Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biosimilars of Rituximab Tier 1, Tier 2, and Tier 3
4 Biosimilars of Rituximab Market by Type
  1. 4.1 Biosimilars of Rituximab Type Introduction
  2. 4.1.1 500mg
  3. 4.1.2 100mg
  4. 4.1.3 Other
  5. 4.2 Global Biosimilars of Rituximab Sales by Type
  6. 4.2.1 Global Biosimilars of Rituximab Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Biosimilars of Rituximab Sales by Type (2021-2032)
  8. 4.2.3 Global Biosimilars of Rituximab Sales Market Share by Type (2021-2032)
  9. 4.3 Global Biosimilars of Rituximab Revenue by Type
  10. 4.3.1 Global Biosimilars of Rituximab Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Biosimilars of Rituximab Revenue by Type (2021-2032)
  12. 4.3.3 Global Biosimilars of Rituximab Revenue Market Share by Type (2021-2032)
5 Biosimilars of Rituximab Market by Application
  1. 5.1 Biosimilars of Rituximab Application Introduction
  2. 5.1.1 Hospital Pharmacy
  3. 5.1.2 Retail Pharmacy
  4. 5.2 Global Biosimilars of Rituximab Sales by Application
  5. 5.2.1 Global Biosimilars of Rituximab Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Biosimilars of Rituximab Sales by Application (2021-2032)
  7. 5.2.3 Global Biosimilars of Rituximab Sales Market Share by Application (2021-2032)
  8. 5.3 Global Biosimilars of Rituximab Revenue by Application
  9. 5.3.1 Global Biosimilars of Rituximab Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Biosimilars of Rituximab Revenue by Application (2021-2032)
  11. 5.3.3 Global Biosimilars of Rituximab Revenue Market Share by Application (2021-2032)
6 Global Biosimilars of Rituximab Sales by Region
  1. 6.1 Global Biosimilars of Rituximab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biosimilars of Rituximab Sales by Region (2021-2032)
  3. 6.2.1 Global Biosimilars of Rituximab Sales by Region (2021-2026)
  4. 6.2.2 Global Biosimilars of Rituximab Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biosimilars of Rituximab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Biosimilars of Rituximab Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Biosimilars of Rituximab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Biosimilars of Rituximab Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Biosimilars of Rituximab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Biosimilars of Rituximab Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Biosimilars of Rituximab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Biosimilars of Rituximab Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Biosimilars of Rituximab Revenue by Region
  1. 7.1 Global Biosimilars of Rituximab Revenue by Region
  2. 7.1.1 Global Biosimilars of Rituximab Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Biosimilars of Rituximab Revenue by Region (2021-2026)
  4. 7.1.3 Global Biosimilars of Rituximab Revenue by Region (2027-2032)
  5. 7.1.4 Global Biosimilars of Rituximab Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Biosimilars of Rituximab Revenue (2021-2032)
  8. 7.2.2 North America Biosimilars of Rituximab Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Biosimilars of Rituximab Revenue (2021-2032)
  11. 7.3.2 Europe Biosimilars of Rituximab Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Biosimilars of Rituximab Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Biosimilars of Rituximab Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Biosimilars of Rituximab Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Biosimilars of Rituximab Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AryoGen Pharmed
  2. 8.1.1 AryoGen Pharmed Company Information
  3. 8.1.2 AryoGen Pharmed Business Overview
  4. 8.1.3 AryoGen Pharmed Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AryoGen Pharmed Biosimilars of Rituximab Product Portfolio
  6. 8.1.5 AryoGen Pharmed Recent Developments
  7. 8.2 Biocad
  8. 8.2.1 Biocad Company Information
  9. 8.2.2 Biocad Business Overview
  10. 8.2.3 Biocad Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Biocad Biosimilars of Rituximab Product Portfolio
  12. 8.2.5 Biocad Recent Developments
  13. 8.3 Cadila Pharmaceuticals
  14. 8.3.1 Cadila Pharmaceuticals Company Information
  15. 8.3.2 Cadila Pharmaceuticals Business Overview
  16. 8.3.3 Cadila Pharmaceuticals Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cadila Pharmaceuticals Biosimilars of Rituximab Product Portfolio
  18. 8.3.5 Cadila Pharmaceuticals Recent Developments
  19. 8.4 Celltrion
  20. 8.4.1 Celltrion Company Information
  21. 8.4.2 Celltrion Business Overview
  22. 8.4.3 Celltrion Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Celltrion Biosimilars of Rituximab Product Portfolio
  24. 8.4.5 Celltrion Recent Developments
  25. 8.5 Dr Reddy’s Laboratories
  26. 8.5.1 Dr Reddy’s Laboratories Company Information
  27. 8.5.2 Dr Reddy’s Laboratories Business Overview
  28. 8.5.3 Dr Reddy’s Laboratories Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dr Reddy’s Laboratories Biosimilars of Rituximab Product Portfolio
  30. 8.5.5 Dr Reddy’s Laboratories Recent Developments
  31. 8.6 Hetero Group
  32. 8.6.1 Hetero Group Company Information
  33. 8.6.2 Hetero Group Business Overview
  34. 8.6.3 Hetero Group Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hetero Group Biosimilars of Rituximab Product Portfolio
  36. 8.6.5 Hetero Group Recent Developments
  37. 8.7 Innovent Biologics
  38. 8.7.1 Innovent Biologics Company Information
  39. 8.7.2 Innovent Biologics Business Overview
  40. 8.7.3 Innovent Biologics Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Innovent Biologics Biosimilars of Rituximab Product Portfolio
  42. 8.7.5 Innovent Biologics Recent Developments
  43. 8.8 Intas Biopharmaceuticals
  44. 8.8.1 Intas Biopharmaceuticals Company Information
  45. 8.8.2 Intas Biopharmaceuticals Business Overview
  46. 8.8.3 Intas Biopharmaceuticals Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Intas Biopharmaceuticals Biosimilars of Rituximab Product Portfolio
  48. 8.8.5 Intas Biopharmaceuticals Recent Developments
  49. 8.9 Probiomed
  50. 8.9.1 Probiomed Company Information
  51. 8.9.2 Probiomed Business Overview
  52. 8.9.3 Probiomed Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Probiomed Biosimilars of Rituximab Product Portfolio
  54. 8.9.5 Probiomed Recent Developments
  55. 8.10 TRPharma
  56. 8.10.1 TRPharma Company Information
  57. 8.10.2 TRPharma Business Overview
  58. 8.10.3 TRPharma Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 TRPharma Biosimilars of Rituximab Product Portfolio
  60. 8.10.5 TRPharma Recent Developments
  61. 8.11 Viatris
  62. 8.11.1 Viatris Company Information
  63. 8.11.2 Viatris Business Overview
  64. 8.11.3 Viatris Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Viatris Biosimilars of Rituximab Product Portfolio
  66. 8.11.5 Viatris Recent Developments
  67. 8.12 Zenotech Laboratories
  68. 8.12.1 Zenotech Laboratories Company Information
  69. 8.12.2 Zenotech Laboratories Business Overview
  70. 8.12.3 Zenotech Laboratories Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Zenotech Laboratories Biosimilars of Rituximab Product Portfolio
  72. 8.12.5 Zenotech Laboratories Recent Developments
  73. 8.13 Amgen
  74. 8.13.1 Amgen Company Information
  75. 8.13.2 Amgen Business Overview
  76. 8.13.3 Amgen Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Amgen Biosimilars of Rituximab Product Portfolio
  78. 8.13.5 Amgen Recent Developments
  79. 8.14 Teva
  80. 8.14.1 Teva Company Information
  81. 8.14.2 Teva Business Overview
  82. 8.14.3 Teva Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Teva Biosimilars of Rituximab Product Portfolio
  84. 8.14.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biosimilars of Rituximab Value Chain Analysis
  2. 9.1.1 Biosimilars of Rituximab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biosimilars of Rituximab Production Mode & Process
  6. 9.2 Biosimilars of Rituximab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biosimilars of Rituximab Distributors
  9. 9.2.3 Biosimilars of Rituximab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst